Enliven Therapeutics (NASDAQ:ELVN) Shares Down 6.1% After Insider Selling

by · The Markets Daily

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price traded down 6.1% on Tuesday after an insider sold shares in the company. The company traded as low as $16.65 and last traded at $16.8450. 448,966 shares traded hands during trading, a decline of 1% from the average session volume of 454,036 shares. The stock had previously closed at $17.93.

Specifically, insider Joseph P. Lyssikatos sold 5,000 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $16.84, for a total transaction of $84,200.00. Following the completion of the transaction, the insider directly owned 897,688 shares of the company’s stock, valued at approximately $15,117,065.92. The trade was a 0.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Read Our Latest Analysis on ELVN

Enliven Therapeutics Trading Up 1.2%

The business has a 50 day moving average of $20.18 and a 200-day moving average of $20.30. The stock has a market cap of $993.17 million, a PE ratio of -9.10 and a beta of 0.35.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. Research analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ELVN. Goldman Sachs Group Inc. grew its stake in Enliven Therapeutics by 61.3% during the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after buying an additional 80,506 shares during the period. Affinity Asset Advisors LLC purchased a new position in Enliven Therapeutics in the 2nd quarter worth approximately $8,024,000. Wellington Management Group LLP grew its holdings in Enliven Therapeutics by 4.7% during the 1st quarter. Wellington Management Group LLP now owns 84,700 shares of the company’s stock valued at $1,667,000 after purchasing an additional 3,784 shares in the last quarter. Ally Bridge Group NY LLC boosted its position in Enliven Therapeutics by 19.8% in the 1st quarter. Ally Bridge Group NY LLC now owns 169,774 shares of the company’s stock valued at $3,341,000 after buying an additional 28,064 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in Enliven Therapeutics during the 1st quarter valued at approximately $2,049,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

See Also